CJC-1295 (No DAC) / IPAMORELIN
Description: This research formulation combines CJC-1295 (No DAC) and Ipamorelin in a dual-peptide preparation. CJC-1295 (No DAC), commonly referenced in research as Modified GRF(1-29), is a stabilized growth hormone-releasing hormone (GHRH) analog used to investigate activation of pituitary GHRH receptors (GHRHR) and downstream signaling involved in pulsatile growth hormone (GH) secretion. Ipamorelin is a selective growth hormone secretagogue receptor agonist (GHS-R/GHS-R1a; ghrelin receptor) that stimulates GH release via a complementary secretagogue pathway. Together, the combination is used in research settings to investigate regulation of pulsatile GH secretion, pituitary signaling, and downstream insulin-like growth factor-1 (IGF-1) responses.
Description
- Contents: 10 mg total (5 mg CJC-1295 No DAC + 5 mg Ipamorelin) / 20 mg total (10 mg CJC-1295 No DAC + 10 mg Ipamorelin)
- Appearance: White lyophilized powder
- Storage: Store frozen (≤ −20 °C) for long-term storage; protect from moisture and light.
- Intended Use: For laboratory research use only
Note: Not for human or veterinary use.
Additional information
| Weight | 0.5 lbs |
|---|---|
| Dimensions | 1 × 1 × 1 in |
| Size | 10mg total (5mg/5mg), 20mg total (10mg/10mg) |
